Please use this identifier to cite or link to this item: https://doi.org/10.21256/zhaw-3625
Full metadata record
DC FieldValueLanguage
dc.contributor.authorSeidl, Astrid-
dc.contributor.authorDanner, Marion-
dc.contributor.authorWagner, Christoph J.-
dc.contributor.authorSandmann, Frank G.-
dc.contributor.authorSroczynski, Gaby-
dc.contributor.authorStürzlinger, Heidi-
dc.contributor.authorZsifkovits, Johannes-
dc.contributor.authorSchwalm, Anja-
dc.contributor.authorLhachimi, Stefan K.-
dc.contributor.authorSiebert, Uwe-
dc.contributor.authorGerber-Grote, Andreas-
dc.date.accessioned2018-05-02T12:47:03Z-
dc.date.available2018-05-02T12:47:03Z-
dc.date.issued2018-
dc.identifier.issn2381-4683de_CH
dc.identifier.urihttps://digitalcollection.zhaw.ch/handle/11475/5732-
dc.description.abstractBackground: Estimating input costs for Markov models in health economic evaluations requires health state-specific costing. This is a challenge in mental illnesses such as depression, as interventions are not clearly related to health states. We present a hybrid approach to health state-specific cost estimation for a German health economic evaluation of antidepressants. Methods: Costs were determined from the perspective of the community of persons insured by statutory health insurance (“SHI insuree perspective”) and included costs for outpatient care, inpatient care, drugs, and psychotherapy. In an additional step, costs for rehabilitation and productivity losses were calculated from the societal perspective. We collected resource use data in a stepwise hierarchical approach using SHI claims data, where available, followed by data from clinical guidelines and expert surveys. Bottom-up and top-down costing approaches were combined. Results: Depending on the drug strategy and health state, the average input costs varied per patient per 8-week Markov cycle. The highest costs occurred for agomelatine in the health state first-line treatment (FT) (“FT relapse”) with €506 from the SHI insuree perspective and €724 from the societal perspective. From both perspectives, the lowest costs (excluding placebo) were €55 for selective serotonin reuptake inhibitors in the health state “FT remission.” Conclusion: To estimate costs in health economic evaluations of treatments for depression, it can be necessary to link different data sources and costing approaches systematically to meet the requirements of the decision-analytic model. As this can increase complexity, the corresponding calculations should be presented transparently. The approach presented could provide useful input for future models.de_CH
dc.language.isoende_CH
dc.publisherSagede_CH
dc.relation.ispartofMDM Policy & Practicede_CH
dc.rightshttp://creativecommons.org/licenses/by-nc/4.0/de_CH
dc.subject.ddc338: Produktionde_CH
dc.titleEstimation of input costs for a Markov model in a German health economic evaluation of newer antidepressantsde_CH
dc.typeBeitrag in wissenschaftlicher Zeitschriftde_CH
dcterms.typeTextde_CH
zhaw.departementGesundheitde_CH
dc.identifier.doi10.21256/zhaw-3625-
dc.identifier.doi10.1177/2381468317751923de_CH
zhaw.funding.euNode_CH
zhaw.issue1de_CH
zhaw.originated.zhawYesde_CH
zhaw.publication.statuspublishedVersionde_CH
zhaw.volume3de_CH
zhaw.publication.reviewPeer review (Publikation)de_CH
Appears in Collections:Publikationen Gesundheit

Files in This Item:
File Description SizeFormat 
2381468317751923.pdf430.69 kBAdobe PDFThumbnail
View/Open


Items in DSpace are protected by copyright, with all rights reserved, unless otherwise indicated.